These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21285184)

  • 21. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.
    Ogawa J; Harigai M; Akashi T; Nagasaka K; Suzuki F; Tominaga S; Miyasaka N
    Ann Rheum Dis; 2006 Dec; 65(12):1667-9. PubMed ID: 17105857
    [No Abstract]   [Full Text] [Related]  

  • 22. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct; 18(103):198-201. PubMed ID: 19882783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab.
    Molloy E; Ramakrishnan S; Murphy E; Barry M
    Rheumatology (Oxford); 2004 Apr; 43(4):522-3. PubMed ID: 15024136
    [No Abstract]   [Full Text] [Related]  

  • 24. Adalimumab-induced cutaneous lupus.
    Sheth N; Greenblatt D; Patel S; Acland K
    Clin Exp Dermatol; 2007 Sep; 32(5):593-4. PubMed ID: 17692063
    [No Abstract]   [Full Text] [Related]  

  • 25. Cutaneous lupus erythematosus induced by adalimumab.
    Vezzoli P; Violetti SA; Serini SM; Muratori S; Berti E; Crosti C
    J Dermatol; 2011 Mar; 38(3):283-4. PubMed ID: 21342233
    [No Abstract]   [Full Text] [Related]  

  • 26. Adalimumab-induced asthma.
    Bennett AN; Wong M; Zain A; Panayi G; Kirkham B
    Rheumatology (Oxford); 2005 Sep; 44(9):1199-200. PubMed ID: 15870147
    [No Abstract]   [Full Text] [Related]  

  • 27. Dermatomyositis during adalimumab therapy for rheumatoid arthritis.
    Brunasso AM; Scocco GL; Massone C
    J Rheumatol; 2010 Jul; 37(7):1549-50. PubMed ID: 20595297
    [No Abstract]   [Full Text] [Related]  

  • 28. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trials. Gene transfer an unlikely contributor to patient's death.
    Kaiser J
    Science; 2007 Dec; 318(5856):1535. PubMed ID: 18063761
    [No Abstract]   [Full Text] [Related]  

  • 30. Adalimumab-induced pityriasis rosea.
    Rajpara SN; Ormerod AD; Gallaway L
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1294-6. PubMed ID: 17894747
    [No Abstract]   [Full Text] [Related]  

  • 31. Miliary tuberculosis after biological therapy for rheumatoid arthritis.
    Rovere Querini P; Vecellio M; Sabbadini MG; Ciboddo G
    Rheumatology (Oxford); 2002 Feb; 41(2):231. PubMed ID: 11886978
    [No Abstract]   [Full Text] [Related]  

  • 32. An atypical varicella exanthem associated with the use of infliximab.
    Choi HJ; Kim MY; Kim HO; Park YM
    Int J Dermatol; 2006 Aug; 45(8):999-1000. PubMed ID: 16911403
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cutaneous rash from the use of medicine for rheumatoid arthritis].
    Hannuksela M
    Duodecim; 2006; 122(1):105, 111. PubMed ID: 16509198
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical safety of tocilizumab in rheumatoid arthritis.
    Bannwarth B; Richez C
    Expert Opin Drug Saf; 2011 Jan; 10(1):123-31. PubMed ID: 21121872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
    Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract]   [Full Text] [Related]  

  • 36. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis.
    Giles JT; Bartlett SJ; Gelber AC; Nanda S; Fontaine K; Ruffing V; Bathon JM
    Arthritis Rheum; 2006 Apr; 55(2):333-7. PubMed ID: 16583385
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
    Sakai R; Tanaka M; Nanki T; Watanabe K; Yamazaki H; Koike R; Nagasawa H; Amano K; Saito K; Tanaka Y; Ito S; Sumida T; Ihata A; Ishigatsubo Y; Atsumi T; Koike T; Nakajima A; Tamura N; Fujii T; Dobashi H; Tohma S; Sugihara T; Ueki Y; Hashiramoto A; Kawakami A; Hagino N; Miyasaka N; Harigai M;
    Ann Rheum Dis; 2012 Nov; 71(11):1820-6. PubMed ID: 22504558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab).
    Chaves Y; Duarte G; Ben-Said B; Tebib J; Berard F; Nicolas JF
    Dermatology; 2008; 217(4):380. PubMed ID: 18849606
    [No Abstract]   [Full Text] [Related]  

  • 39. Disseminated tuberculosis after anti-TNFalpha treatment.
    Malipeddi AS; Rajendran R; Kallarackal G
    Lancet; 2007 Jan; 369(9556):162. PubMed ID: 17223480
    [No Abstract]   [Full Text] [Related]  

  • 40. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.